Migräne

Literatur

• 1 Diener H C, Brune K, Gerber W D, Pfaffenrath V, Straube A. Therapie der Migräneattacke und Migräneprophylaxe. Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG).  Akt Neurologie. 2000;  27 273-282
• 2 Olesen J, Bousser M-G, Diener H, Dodick D, First M, Goadsby P, Göbel H, Lainez M, Lance J, Lipton R, Nappi G, Sakai F, Schoenen J, Silberstein S, Steiner T. for the International Headache Society . The International Classification of Headache Disorders. 2^nd Edition.  Cephalalgia. 2004;  24 (Suppl 1) 1-160
• 3 Sances G GF, Nappi R E, Fignon A, Ghiotto N, Polatti F, Nappi G. Course of migraine during pregnancy and postpartum: a prospective study.  Cephalalgia. 2003;  23 197-205
• 4 Honkasalo M, Kaprio J, Winter T. Migraine and concomitant symptoms among 8167 adult twin pairs.  Headache. 1995;  35 70-78
• 5 Ulrich V, Gervil M, Kyvik K O, Olesen J, Russell M B. Evidence of a genetic factor in migraine with aura: a population based Danish twin study.  Annals of Neurology. 1999;  45 242-246
• 6 Ophoff R A, Terwindt G M, Vergouwe M N, Eijk R V, Oefner P J, Hoffman S MG, Lamerdin J E, Mohrenweiser H W, Bulman D E, Ferrari M, Haan J, Lindhout D, Ommen G-J Bv, Hofker M H, Ferrari M D, Frants R R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNLA4.  Cell. 1996;  87 543-552
• 7 Ophoff R A, Terwindt G M, Vergouwe M N, Frants R R, Ferrari M D. on behalf of the Dutch Migraine Genetics Research Group . Involvement of a Ca channel gene in familial hemiplegic migraine and migraine with and without aura.  Headache. 1997;  37 479-485
• 8 Tfelt-Hansen P, Block G, Dahlof C, Diener H C, Ferrari M D, Goadsby P J, Guidetti V, Jones B, Lipton R B, Massiou H, Meinert C, Sandrini G, Steiner T, Winter P B. for the International Headache Society Clinical Trials Subcommittee . Guidelines for controlled trials of drugs in migraine: second edition.  Cephalalgia. 2000;  20 765-786
• 9 Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H. Features of medication overuse headache following overuse of different acute headache drugs.  Neurology. 2002;  59 1011-1014
• 10 Fox A. Comparative tolerability of oral 5-HT1B/1D agonists.  Headache. 2000;  40 521-527
• 11 O'Quinn S, Davis R L, Guttermann D L, Pait G D, Fox A W. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine.  Cephalalgia. 1999;  19 223-231
• 12 Limmroth V, May A, Diener H-C. Lysine-acetylsalicylic acid in acute migraine attacks.  Eur Neurol. 1999;  41 88-93
• 13 Fisher M A, Glass S. Butorphanol (Stadol): A study in problems of current drug information and control.  Neurology. 1997;  48 1156-1160
• 14 Diener H C. und die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) .Leitlinien für Diagnostik und Therapie in der Neurologie. 2. ed. Stuttgart: Thieme 2003
• 15 Ernst E. Homeopathic prophylaxis of headache and migraine. A systematic review.  J Pain Symptom Manage. 1999;  18 353-357
• 16 Walach H, Haeusler W, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G, Gaus W, Haag G. Classical homeopathic treatment of chronic headaches.  Cephalalgia. 1997;  17 119-126
• 17 Melchart D, Linde K, Fischer P, White A, Allais G, Vickers A, Berman B. Acupuncture for recurrent headaches: a systematic review of randomised controlled trials.  Cephalalgia. 1999;  19 779-786
• 18 Pfaffenrath V, Diener H C, Fischer M, Friede M, Henneicke-von Zeppelin H H. on behalf of the Investigators . The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a double-blind, multicentre, randomized placebo-controlled dose-response study.  Cephalalgia. 2002;  22 523-532
• 19 Palevitch D, Earon G, Carasso R. Feverfew (tanacetum parthenium) as a prophylactic treatment for migraine - a double blind placebo-controlled study.  Phytother Res. 1997;  11 508-511